Solid Biosciences

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneider, Chief Technology Officer and Cathryn Clary, Interim Chief Medical Officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Tuesday, October 6, 2020 at 4:45 pm ET.

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference

Solid Biosciences Inc. (NASDAQ: SLDB) shares more than doubled on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA). Essentially, the agency has decided to lift a clinical hold placed on the firm in July 2020.

Why Solid Bio’s Future Just Got a Lot Brighter

– Modifications to IGNITE DMD trial protocol and improvements to manufacturing processes enable continued program development –

Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

NEW YORK, July 29, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB

CAMBRIDGE, Mass., July  24, 2020  (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the Company’s IGNITE DMD Phase I/II clinical trial remains on clinical hold.

Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold

CAMBRIDGE, Mass., June  18, 2020  (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of board member Ian F. Smith as Chairman of the Board. Mr. Smith succeeds Andrey Zarur, Ph.D., who served as Chairman of the Board since 2013 and is one of the co-founders of Solid Biosciences. The appointment is effective June 16, 2020.

Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors

Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Solid Biosciences (SLDB) Stock Might be a Great Pick

CAMBRIDGE, Mass., May  07, 2020  (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that it received written communication from the U.S. Food and Drug Administration (FDA) regarding the clinical hold placed on the Company’s IGNITE DMD Phase I/II clinical trial. The program remains on clinical hold and the Company will continue to work with the FDA to address their requests. 

Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD

Atara Biotherapeutics

Biohaven Pharmaceutical Hld

CymaBay Therapeutics

Marinus Pharmaceuticals

PTC Therapeutics

Telesis Bio Inc

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

7 Disruptive Biotech Stocks to Buy for 2025

Smith to Deepen Strategic Leadership and Complement Commercial, Operational and Financial Expertise of the Board

Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors

The company announced plans to slash its head count and go all in on a single gene therapy. Is that wise or stubborn?

Here's Why Solid Biosciences Fell as Much as 16.3% Today

CAMBRIDGE, Mass., Jan.  09, 2020  (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne). In December 2019, the company reported biomarker data from two patients that provide evidence that SGT-001 is biologically active with differentiated properties which Solid believes warrants further evaluation.

Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

Early data for its side-effect-ridden gene therapy SGT-001 doesn't look very promising.

Here's Why Solid Biosciences Stock Got Hammered Today

Solid Biosciences Inc. (NASDAQ: SLDB) shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy (DMD).

Is Solid Biosciences in Trouble After This Duchenne Muscular Dystrophy Update?

Solid Biosciences Inc (NASDAQ: SLDB) shares are advancing strongly Wednesday following on an update on its clinical development program for its SGT-001, its gene transfer investigational candidate for Duchenne muscular dystrophy, or DMD.

Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug

Shares of Solid Biosciences Inc. SLDB, +7.99% gained 22% in premarket trading on Wednesday after the company said two patients who received doses of its experimental Duchenne muscular dystrophy (DMD) treatment showed that the therapy "has the potential" to benefit them.

Solid Biosciences stock are up on DMD study news

- Demonstrated  expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit for patients with Duchenne

Solid Biosciences Provides Data Update from SGT-001 Development Program

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Solid Biosciences (SLDB) Stock

Solid Biosciences: Amid The Difficulty Is An Opportunity

A clinical trial evaluating the company's lead drug candidate was placed on a clinical hold -- for the third time.

Here's Why Solid Biosciences Collapsed Today

Solid Biosciences Inc (NASDAQ: SLDB) shares pulled back to all-time lows Tuesday after the company said its lead gene therapy candidate to treat Duchenne muscular dystrophy has been placed on clinical hold by the FDA yet again.

Solid Biosciences Shares Crash To Record Low After FDA Places Gene Therapy Program On Hold

Company to hold conference call at 8:30 AM ET today Company to hold conference call at 8:30 AM ET today

Solid Biosciences Provides SGT-001 Program Update

CBL & Associates Properties

First Solar

Nautilus

Pier 1 Imports

Tesla

With the markets at all-time highs, no one is thinking about stocks to sell. And that’s one of the reasons why you should think exactly that.

7 Stocks to Sell Before They Roll Over

The clinical-stage biopharma announced changes to its lead pipeline program. Will it be enough?

Here's Why Solid Biosciences Is Soaring Today

The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.

News for Solid Biosciences Stock (SLDB)